Reprogramming Immune Cells for Targeted Cancer Therapy

40 concepts29 papers1 proposal

Standard cancer treatments often struggle to distinguish between malignant and healthy tissue, leading to systemic toxicity. While the immune system is naturally equipped to kill abnormal cells, tumors frequently evade detection by downregulating visibility markers or creating immunosuppressive environments. Adoptive cellular immunotherapy bypasses these defenses by extracting a patient’s immune cells, genetically "reprogramming" them to recognize specific tumor markers, and re-infusing them as a living drug.

The Two Ways of Seeing: CARs vs. TCRs

To kill a tumor, an immune cell must first see it. Researchers have developed two primary synthetic "eyes" to grant this vision: Chimeric Antigen Receptors (CARs) and engineered T-cell Receptors (TCRs).

Chimeric Antigen Receptors (CARs) are synthetic proteins that combine an extracellular antibody-like recognition domain with intracellular signaling triggers. As Minfeng Yang et al. explain, CAR T-cells are engineered to recognize antigens directly on the cell surface. The primary advantage of this mechanism, noted by Shi Du et al., is that it bypasses the need for Major Histocompatibility Complex (MHC) presentation. Because many tumors survive by "hiding" their MHC molecules, CAR-based recognition ensures the immune cell can still lock onto its target.

TCR-engineered T cells (TCR-T), by contrast, use modified versions of natural receptors. While CARs only see surface proteins, TCRs can "see" inside the cancer cell. They recognize small peptide fragments derived from internal cellular proteins that are shuttled to the surface by MHC molecules. Yikai Zhang et al. argue that this allows TCR-T therapy to target a much broader range of tumor-specific mutations, including those that do not result in surface-expressed proteins.

Bypassing Immune Tolerance

A fundamental challenge in engineering these receptors is the body’s own safety filter: central tolerance. During development, the immune system purges T-cells that bind too strongly to "self" proteins to prevent autoimmunity. Unfortunately, many tumor antigens are slightly modified versions of self-proteins, meaning the most effective "killer" cells have already been deleted by the body.

Asiel A. Benitez et al. demonstrated a way to circumvent this by using mice deficient in Aire, the gene responsible for this purging process. By harvesting the "forbidden" T-cells that survive in these mice, researchers can identify high-affinity TCRs that the human body would normally never produce. These "tolerance-bypass" receptors can then be cloned into a patient’s T-cells to create a more potent anti-tumor response.

Expanding Beyond T-Cells

While T-cells are the workhorses of adoptive therapy, they carry risks, such as cytokine release syndrome (a dangerous systemic inflammatory response). This has led to the development of CAR-NK cells, which use Natural Killer cells as the chassis.

Pengcheng Zuo et al. show that CAR-NK cells can effectively inhibit tumor growth in pediatric brain tumors without the severe inflammatory side effects typical of CAR-T cells. Furthermore, Changqing Pan et al. found that optimizing the CAR signaling domains specifically for NK cell biology—rather than just borrowing T-cell components—significantly improves their anti-tumor activity. This shift toward cell-type-specific engineering allows for "off-the-shelf" therapies that are safer and more scalable than patient-specific T-cell products.

Overcoming the Solid Tumor Barrier

Adoptive therapy has seen massive success in "liquid" blood cancers, but solid tumors like glioblastoma and colorectal cancer remain difficult targets. The authors of several studies identify three main hurdles:

  1. Antigen Heterogeneity: Not every cell in a solid tumor expresses the same marker. Jiatao Hu et al. suggest using dual-targeting CARs or nanobody-based designs to prevent "antigen escape," where the tumor survives by losing the single protein the T-cells were trained to find.
  2. Infiltration: T-cells often struggle to physically enter the dense environment of a solid tumor. Can Zhu et al. proposed a hybrid approach: using Tumor-Infiltrating Lymphocytes (TILs)—cells that have already proven they can find the tumor—and engineering them with CARs to boost their killing power.
  3. The Immunosuppressive Microenvironment: Tumors create "immune deserts" that exhaust T-cells. Kai Ding et al. and Jianmei Li et al. highlight how combining engineered cells with personalized mRNA vaccines can "turn up the heat" on these cold tumors, priming the immune system to maintain a long-lasting memory of the cancer.

Precision Targeting

The success of these therapies depends entirely on the choice of target. Emerging research has identified several high-priority antigens that are prevalent on tumors but scarce in healthy tissue:

  • GD2: A glycolipid highly expressed in lethal pediatric brain cancers like H3K27M-mutated diffuse midline gliomas. Robbie G. Majzner et al. demonstrated that GD2-targeted CAR T-cells can produce radiographic improvements in these aggressive tumors.
  • B7-H3 (CD276): An immune checkpoint molecule overexpressed in various solid tumors. Shuo Yang et al. describe it as a prime target for precision oncology due to its role in tumor progression and its absence in healthy cells.
  • CD70: A protein emerging as a dual-purpose target for both diagnosis and therapy, particularly when targeted by allogeneic (donor-derived) CAR-NK cells Jiatao Hu et al..

By combining these precise targets with sophisticated cellular engineering, adoptive immunotherapy is evolving from a broad-spectrum tool into a personalized, programmable weapon against the most treatment-resistant cancers.

Key Foundational Work

Personalized Chimeric Antigen Receptor T- Cell Immunotherapy for Patients with Recurrent Malignant Gliomas (2018) — contributed 3 concept elements to this direction.
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives (2020) — contributed 1 concept elements to this direction.
B7-H3, a checkpoint molecule, as a target for cancer immunotherapy (2020) — contributed 1 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_adoptive_cellular_immunotherapy_8dbab90c,
  title = {adoptive cellular immunotherapy},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/adoptive-cellular-immunotherapy/rdr_8dbab90c83884691863b9f30e4b56430},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 1, frozen text):

@misc{lacuna_adoptive_cellular_immunotherapy_8dbab90c_v1,
  title = {adoptive cellular immunotherapy},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/adoptive-cellular-immunotherapy/rdr_8dbab90c83884691863b9f30e4b56430/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake